



Published in final edited form as:

Tetrahedron Lett. 2015 June 3; 56(23): 3624–3629. doi:10.1016/j.tetlet.2015.01.129.

Mechanistic Considerations in the Synthesis of 2-Aryl-Indole Analogues under Bischler-Mohlau Conditions

Matthew T. MacDonough^a, Zhe Shi^a, and Kevin G. Pinney^{a,*}

^aDepartment of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States of America (USA)

Abstract

Mechanistic insight into the pathway of the Bischler-Mohlau indole formation reaction is provided by isotopic labeling utilizing judicious incorporation of a ¹³C atom within the α-bromoacetophenone analogue reactant. The resulting rearranged 2-aryl indole, isolated as the major product, located the ¹³C isotope label at the methine carbon of the fused five-membered heterocyclic ring, which suggested that the mechanistic pathway of cyclization, in this specific example, required two equivalents of the aniline analogue reactant partner and proceeded through an imine intermediate rather than by direct formation of the corresponding 3-aryl indole accompanied by a concomitant 1,2-aryl shift rearrangement.

Keywords

Bischler-Mohlau Indole Synthesis; Indole Synthesis; Mechanistic Investigation; ¹³C Atom Incorporation

Introduction

In the context of a long-standing program focused on the design, synthesis, and biological evaluation of diversely functionalized small-molecule anticancer agents, a series of benzo[*b*]thiophene,^{1–3} benzo[*b*]furan,^{4–5} and indole-based^{6–8} analogues emerged as promising potential pre-clinical candidates (Fig. 1). These compounds were designed to function as inhibitors of tubulin polymerization (assembly) that bind to the colchicine site on the tubulin heterodimer and certain of these compounds demonstrated a dualistic mechanism of action functioning both as potent antiproliferative agents and as pronounced vascular disrupting agents (VDAs).^{9–10} In each case, the heterocyclic fused ring was introduced synthetically through an efficient ring-closing step, and it proved intriguing to consider

*Corresponding author. Tel.: 254-710-4117, Kevin_Pinney@baylor.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data.

Supplementary data (Experimental procedures, ¹H NMR, ¹³C NMR, DEPT NMR, HRMS, and HPLC data, along with X-ray crystallographic data) associated with this article can be found, in the online version, at {to be completed later}.

whether this reaction in the indole series of analogues mirrored that of the benzo[*b*]thiophene series or was mechanistically distinct.

The indole core ring system continues to be utilized as an abundant molecular scaffold in medical chemistry¹¹ and represent an important class of heterocycles.¹² The mechanistic pathways and synthetic routes available towards the indole platform are well established and vary greatly.¹³ One established approach, referred to as the Fischer indole synthesis, involves a [3,3]-sigmatropic rearrangement followed by closure to the fused five-membered ring. This method was first pioneered by Fischer in 1883¹⁴ and continues to be explored today.¹⁵ Another frequently utilized approach is the Bischler-Mohrlau indole synthesis^{16–18} that involves the reaction between aniline analogues and α -halogenated ketone analogues and results in both 2-aryl and 3-aryl indole regioisomers. While the Bischler-Mohrlau reaction^{19–24} accommodates a wide-range of functionalized α -bromoketones and aniline analogues as starting materials, low isolated yields and unpredictable regiochemistry^{25–26} remain potentially problematic. The reaction is heavily substrate dependent (in terms of yield and regiochemical outcome) and modifications in reaction conditions, including microwave heating,²⁵ can dramatically influence the overall process.²⁶ The perceived simplicity of the Bischler-Mohrlau reaction somewhat disguises the complex mechanistic pathways which can lead to both 2-aryl and 3-aryl indole analogues. The indole product (2-aryl or 3-aryl) is dependent on one of several potential mechanistic pathways. These pathways were further investigated by Vara and co-workers by assessing the activation energies associated with intermediates and transition states.²⁶ Pathway A (Scheme 1) involves initial displacement of a bromine atom from 2-bromoacetophenone or an appropriately functionalized 2-bromoacetophenone analogue by aniline or an analogous aniline analogue. The pathway proceeds through intramolecular cyclization and subsequent re-aromatization to afford non-rearranged 3-aryl indole **4**.

A well-recognized competing Pathway B (Scheme 2), which most often is invoked as being predictive of the major product of the Bischler-Mohrlau indole synthesis, initiates in a similar fashion with the aniline analogue (3-methoxyaniline in this example) displacing the bromine atom on the α -bromoacetophenone analogue (compound **1** in this example). Condensation with a second molecule of 3-methoxyaniline results in the formation of imine intermediate **5**, which upon intramolecular cyclization involving displacement of the initial aniline molecule and subsequent tautomerization of 2-aryl indole **7**, generates the stable 2-aryl indole tautomer **8**. Previous computational and experimental studies have suggested that pathway B is preferred when an excess of aniline is used.²⁶ It should be noted that Vara and co-workers have evaluated another mechanistic possibility leading to formation of rearranged indole products (such as **8**), through an interesting carbonyl-shift rearrangement of a ketone (such as **3**) to an aldehyde prior to cyclization.^{26–28}

We were intrigued by the possibility that a 3-aryl-indole analogue formed through pathway A could perhaps undergo a subsequent 1,2 aryl shift (pH dependent) resulting in a rearranged 2-aryl-indole analogue as the thermodynamic sink under these reaction conditions (Scheme 3).^{29–30}

This postulated methodology (1,2-aryl shift in the indole system under Bischler-Mohrlau conditions) is somewhat reminiscent of previous studies with related benzo[*b*]thiophene ring systems in which alpha-thio-ketone **III** (Scheme 4), for example, was converted to benzo[*b*]thiophene regioisomers **IV** and **V** upon treatment with PPA.^{1,31–32} The mechanism is widely thought to involve concomitant cyclization and 1,2 aryl ring migration. The regioisomers in this example result from initial cyclization occurring either *ortho* or *para* to the methoxy group on the aryl ring of the sulfide.^{1,31–32}

In an effort to further explore the Bischler-Mohrlau reaction pathways a ¹³C isotopic labeling strategy was developed in which the α-carbon (to the carbonyl) was selectively labeled with ¹³C. This labeled carbon atom can be readily traced through the identification of key distinct ¹³C NMR signatures, specifically ¹³C DEPT NMR, thus providing evidence for which mechanistic pathway predominates in this specific indole-forming reaction sequence (Scheme 5).

The synthetic route to ¹³C-labeled bromoacetophenone intermediate **16** followed a similar sequence as the non-labeled bromoacetophenone intermediate from our previous studies with the indole based vascular disrupting agent (VDA) OXi8006^{6–7,33} along with related work by von Angerer and co-workers,³⁴ and simply replaces the traditional methylation step reagents to install the ¹³C carbon atom at the alpha position (Scheme 6).

Protection of 3-hydroxy-4-methoxybenzaldehyde (*isovanillin*) with TBSCl in the presence of Et₃N and catalytic DMAP afforded TBS-aldehyde **11** which was subsequently treated with *in situ* generated ¹³CH₃MgI (from commercially available ¹³CH₃I) to yield ¹³C-labeled secondary alcohol **12**. PCC mediated oxidation generated ¹³C-labeled acetophenone **13**, which after enolization was trapped as its corresponding silyl enol ether **14** upon reaction with TMSCl. Bromination of ¹³C-labeled enol ether **14** afforded requisite ¹³C-labeled bromoacetophenone intermediate **15**, which was treated with greater than three molar equivalents of 3-methoxyaniline (*m*-anisidine) **2** in *N,N*-dimethylaniline at 170 °C (Bischler-Mohrlau conditions) for 12 h to afford rearranged ¹³C-labeled 2-aryl indole **16** (Scheme 6).

It is important to note that there are four possible indole regioisomers that can result from this transformation (Fig. 2) depending on whether the initial cyclization takes place *para* or *ortho* to the methoxy group, with or without rearrangement. In our hands, with this specific set of reactants and these reaction conditions, only one regioisomer was isolated and it was identified as the regioisomer in which the ¹³C atom label was located at the methine carbon (C-3 position of the indole core), suggesting that the system proceeded mechanistically through pathway B (imine intermediate formation) to generate the rearranged 2-aryl indole analogue **16**. The Bischler-Mohrlau reaction to form indole analogue **16** was repeated twice for verification. In the first case, the isolated/purified yield of indole **16** was somewhat low (23%), however in the repeated experiment this yield rose to 73% (91% pure by HPLC), and a subsequent recrystallization afforded a pure sample (see Supplementary data for pertinent spectra). Initial comparison of the ¹³C-NMR of indole regioisomer **16** (Fig. 3) with the predicted spectra (ChemBioDraw Ultra, Version 13.0.2.3020) for each of the four regioisomers, also taking into account the differences in the ¹H-NMR coupling patterns in the A-ring between the *para* and *ortho* ring closed possible products, strongly suggested

regioisomer **16** as the major (and only identified and characterized) product of this reaction (both the initial reaction and the repeated reaction). DEPT ^{13}C NMR analysis (Fig. 3) confirmed that the ^{13}C atom label was located on a methine carbon, thus providing further evidence in support of regioisomer **16**. X-ray crystallographic analysis³⁵ of indole regioisomer **16** provided unequivocal confirmation of its structural assignment (see Supplementary data).

Judicious incorporation of a ^{13}C label provided compelling evidence that the indole ring closure occurred (at least in this example) through a Bischler-Mohrlau pathway rather than a Friedel-Crafts type ring closure, re-aromatization, accompanied by a concomitant aryl ring migration sequence that was envisioned as a potential competing pathway based on early studies suggesting that certain benzo[*b*]thiophene systems undergo ring-closure through this pathway under polyphosphoric acid (PPA) conditions. These results suggest that further inquiry into these and related systems may prove fruitful in delineating and predicting mechanistic pathways based (perhaps) on functional group incorporation and choice of reaction conditions, thus expanding the canopy of indole, benzo[*b*]thiophene, benzo[*b*]furan, and related small-molecule anticancer agents accessible under these synthetic protocols.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors are grateful to the National Cancer Institute of the National Institutes of Health (grant no. 5R01CA140674 to K.G.P.) and OXiGENE Inc. (grant to K.G.P.) for their financial support of this project, and to the NSF for funding the Varian 500 MHz NMR spectrometer (grant no. CHE- 0420802). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health. The authors also thank Dr. Alejandro Ramirez (Mass Spectrometry Core Facility, Baylor University), and Dr. Kevin Klausmeyer (X-ray analysis at Baylor University).

References Cited

1. Pinney KG, Bounds DA, Dingeman KM, Mocharla VP, Pettit GR, Bai R, Hamel E. *Bioorg. Med. Chem. Lett.* 1999; 9:1081. [PubMed: 10328289]
2. Chen Z, Mocharla VP, Farmer JM, Pettit GR, Hamel E, Pinney KG. *J. Org. Chem.* 2000; 65:8811. [PubMed: 11112609]
3. Mullica DF, Pinney KG, Mocharla VP, Dingeman KM, Bounds AD, Sappenfield EL. *J. Chem. Crystallogr.* 1998; 28:289.
4. Mocharla, VP. Ph.D. Dissertation. Waco, TX: Baylor University; 1999. Design, Synthesis, and Biological Evaluation of Diverse Small Molecular Frameworks as Tubulin Binding Ligands.
5. Kessler, RJ. M.S. Thesis. Waco, TX: Baylor University; 2002. Synthesis and Evaluation of New Inhibitors of Tubulin Polymerization and Their Corresponding Prodrugs as Potential Vascular Targeting Agents.
6. Hadimani MB, Kessler RJ, Kautz JA, Ghatak A, Shirali R, O'Dell H, Garner CM, Pinney KG. *Acta Crystallogr.* 2002; C58:330.
7. Hadimani MB, MacDonough MT, Ghatak A, Strecker TE, Lopez R, Sriram M, Nguyen BL, Hall JJ, Kessler RJ, Shirali AR, Liu L, Garner CM, Pettit GR, Hamel H, Chaplin DJ, Mason RP, Trawick ML, Pinney KG. *J. Nat. Prod.* 2013; 76:1668. [PubMed: 24016002]
8. MacDonough MT, Strecker TE, Hamel E, Hall JJ, Chaplin DJ, Trawick ML, Pinney KG. *Bioorg. Med. Chem. Lett.* 2013; 21:6831.

9. Pinney, KG. In: Siemann, D., editor. *Vascular-Targeted Therapies in Oncology*. London, UK: John Wiley & Sons; 2006. p. 95-121.
10. Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. *Integr. Biol.* 2011; 3:375.
11. Roughley SD, Jordan AM. *J. Med. Chem.* 2011; 54:3451. [PubMed: 21504168]
12. Sundberg, RJ. *Comprehensive Heterocyclic Chemistry II*. Katritzky, AR.; Rees, CW.; Scriven, EFV.; Bird, CW., editors. Oxford, UK: Pergamon Press; 1992.
13. Taber DF, Tirunahari PK. *Tetrahedron.* 2011; 67:7195. [PubMed: 25484459]
14. Fischer E, Jourdan F. *Chem. Ber.* 1883; 16:2241.
15. Downing, RS.; Kunkeler, PJ. *The Fischer Indole Synthesis*. Sheldon, RA.; Bekkum, H., editors. New York: Wiley-VCH: Weinheim; 2001.
16. Bischler A, Brion H. *Chem. Ber.* 1892; 25:2860.
17. Bischler A, Firemann P. *Chem. Ber.* 1893; 26:1336.
18. Mohlau R. *Chem. Ber.* 1881; 14:173.
19. Bunescu A, Piemontesi C, Wang Q, Zhu J. *Chem. Commun.* 2013; 49:10284.
20. Bigot P, Saint-Ruf G, Buu-Hoi NP. *J.C.S. Perkin I.* 1972:2573.
21. Bancroft KCC, Ward TJ. *J.C.S. Perkin I.* 1974:1852.
22. Henry JR, Dodd JH. *Tetrahedron Lett.* 1998; 39:8763.
23. Laube M, Tondera C, Sharma SK, Bechmann N, Pietzsch F-J, Pigorsch A, Kockerling M, Wuest F, Pietzsch J, Kniess T. *RSC Adv.* 2014; 4:38726.
24. Li, JJ. *Name Reactions*. Berlin Heidelberg: Springer-Verlag; 2009. p. 46-47.
25. Sridharan V, Perumal S, Avendano C, Menendez JC. *Synlett.* 2006:91.
26. Vara Y, Aldaba E, Arrieta A, Pizarro JL, Arriortua MI, Cossio FP. *Org. Biomol. Chem.* 2008; 6:1763. [PubMed: 18452011]
27. Nelson KL, Seefeld R. *J. Am.Chem. Soc.* 1958; 80:5957.
28. Nelson KL, Robertson J, Duvall JJ. *J. Am.Chem. Soc.* 1963; 86:684.
29. MacDonough, MT.; Zhe, S.; Pinney, KG. Abstracts of Papers; 69th Southwest Regional Meeting of the American Chemical Society; November 16- 19, 2013; Waco, TX. SWRM-229
30. MacDonough, MT. Ph.D. Dissertation. Waco, TX: Baylor University; 2013. The Design, synthesis, and Biological Evaluation of Indole-based Anticancer Agents.
31. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA. *J. Med. Chem.* 1984; 27:1057. [PubMed: 6431104]
32. Kost AN, Budylin VA, Matveeva ED, Sterligov DO. *Zh. Org. Khim.* 1970; 6:1503.
33. Pinney KG, Wang F, Del Pilar Mejia M. *PCT Int. Appl.* 2001 WO 2001019794 A2 20010322.
34. Kaufmann D, Pojarova M, Vogel S, Liebl R, Gastpar R, Gross D, Nishino T, Pfaller T, von Angerer E. *Bioorg. Med. Chem.* 2007; 15:5122. [PubMed: 17533132]
35. Crystallographic data for ^{13}C labeled indole regioisomer **16** presented in this paper have been deposited with the Cambridge Crystallographic Data Centre (CCDC deposition number 1041417). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033 or deposit@ccdc.cam.ac.uk).






Figure 1. Representative Examples of Inhibitors of Tubulin Polymerization Incorporating Fused Heterocyclic Ring Systems: Benzo[*b*]thiophene (A);¹⁻³ Benzo[*b*]furan (B);⁴⁻⁵ and Indole (C)⁶⁻⁸

Cyclization *para* to methoxy group




(with rearrangement)




(no rearrangement)

Cyclization *ortho* to methoxy group



(with rearrangement)



(no rearrangement)

Figure 2.
Four Possible Indole Regioisomers from Representative Bischler-Mohrlau Reaction







Figure 3. ^{13}C -NMR of Unlabeled Indole Analogue **8**, ^{13}C -NMR of ^{13}C Labeled Indole Analogue **16** (same as indole **8** but incorporating ^{13}C label), DEPT NMR of ^{13}C Labeled Indole Analogue **16**.




Scheme 1.
Mechanistic Pathway A Associated with the Bischler-Mohlau Reaction





Scheme 2.
Mechanistic Pathway B Associated with the Bischler-Mohrlau Reaction.




Scheme 3.
Postulated 1,2-Aryl Shift Resulting in Rearranged Indole Analogue.

**Scheme 4.**

Formation of Benzo[*b*]thiophene Regioisomers Via Cyclization and Concomitant 1,2-Aryl Ring Migration.

Pathway A* denotes ^{13}C **Pathway B**

Scheme 5.
Potential Mechanistic Pathways Leading to ^{13}C Labeled Indole Analogues

* denotes ^{13}C 

Scheme 6.
Synthesis of ^{13}C Labeled bromoacetophenone **15** and 2-aryl indole **16**